Skip to Main Content

Paper Details

Safety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic Nephropathy: TRACTION-2 Trial Design.
Kidney Int Rep
11
2021
DN, Diabetic Nephropathy, FSGS, Focal Segmental Glomerulosclerosis, GFB-887, Minimal Change Disease, Patients, Rac1, TR-MCD, TRACTION, TRPC5, TRPC5 Channel, chronic kidney disease, diabetic nephropathy, focal segmental glomerulosclerosis, glomerular kidney, human, minimal change disease, patients, podocyte, proteinuria, renin, transient receptor potential canonical-5, urinary Rac1
Author NameAffiliation
John F ReillyInc.
John F ReillyInc.
Debbie S GipsonUniversity of Michigan ann arbor
  • 1 - 3

Datasets

Release 1.2